scientist envis treat five 15 aid
patient also suffer aids-link
malign b-cell lymphoma patient slate
undergo bone-marrow transplant treatment
cancer short procedur doctor plan
insert special genet alter cell treat virus
test new treatment got green light
nation institut health recombin dna advisori
committe gain approv u.s. food drug
administr januari
aim experi flood bodi
patient huge number killer t-cell
specif target immun cell attack kill
aids-infect cell case experi go awri
provok toxic side effect killer cell equip
gene act so-cal suicid switch enabl
doctor turn experi simpli give
patient antibiot
suicid gene splice killer cell
use classic genet engin techniqu
techniqu employ mouse-tumor virus tool insert
gene render cell sensit antibiot
ganciclovir insert gene act switch
scientist use inactiv killer cell turn
experi dose ganciclovir
treat immune-suppress patient one billion
virus-fight cell delic procedur risk
immun reaction might becom over-exuber explain
team leader philip a. greenberg hutchinson center
re tri rebuild enorm immun respons
patient said dr. greenberg interview
potenti immun respons might
strong might caus inflamm brain lung
suicid switch realli broaden safeti margin
experi
far american scientist use gene therapi
sever separ test treat cancer patient children
hereditari immun weak known ada defici
experi led drs steven a. rosenberg
w. french anderson nation institut health
third gene therapi treatment patient hereditari
high cholesterol approv nih take place
univers michigan
one gene therapi pioneer dr. anderson nih call
seattl experi excit import
protocol
relat move immunex announc plan spin
target genet corp. unit pursu gene therapi
independ compani follow plan privat placement
stock biotech firm said retain 40 % stake
new compani
